Madrigal Pharmaceuticals Announces Inducement Awards

Biopharmaceutical company grants equity awards to new non-executive employees

Feb. 5, 2026 at 11:31pm

Got story updates? Submit your updates here. ›

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced that it granted equity awards on February 1, 2026 to 21 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan.

Why it matters

The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4), which allows companies to grant inducement awards to new employees as a way to attract talent and incentivize them to join the company.

The details

The new employees received, in the aggregate, 5,861 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards is subject to each employee's continued employment as of the applicable vesting date.

  • Madrigal granted the equity awards on February 1, 2026.

The players

Madrigal Pharmaceuticals, Inc.

A biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).

Madrigal's 2025 Inducement Plan

The equity incentive plan under which Madrigal granted the inducement awards to the new non-executive employees.

Got photos? Submit your photos here. ›

The takeaway

Madrigal's inducement awards demonstrate the company's commitment to attracting and retaining top talent as it continues to develop novel treatments for MASH, a liver disease with high unmet medical need.